

**From:** [Giordano, Erica](#)  
**To:** [Patel, Manisha \(manisha.patel@novartis.com\)](#)  
**Cc:** ["Riggins, Cindy"; narin.ahmed@novartis.com](#)  
**Subject:** BL 125646 Clinical Information Request  
**Date:** Friday, August 04, 2017 8:58:56 AM  
**Attachments:** [image001.png](#)

---

Good morning,

Please see the information request below and provide a response by COB today August 4, 2017. As usual please provide the information as a response to this e-mail and submit the information as an official amendment to the BLA.

1. For Subject **(b) (6)** : Please provide the deleted CRF for cytokine release syndrome. We were unable to locate it in the soft deleted eCRFs.
2. Please send us the Medra terms that you used to determine acute kidney injury. We are in receipt of your previous information but still are having an issue with collating the information.

Please confirm receipt of this request.

Thank you,

**Erica Giordano**

*Regulatory Project Manager*

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

U.S. Food and Drug Administration

Tel: 240-402-8298

[Erica.Giordano@fda.hhs.gov](mailto:Erica.Giordano@fda.hhs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."